12:00 AM
 | 
Nov 11, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Vascepa icosapent ethyl regulatory update

Amarin disclosed in its 3Q13 earnings that it began the formal process to appeal FDA's rescission of an SPA for the biotech's Phase III ANCHOR trial, which evaluated Vascepa icosapent ethyl in combination with statins to treat high triglycerides - defined as triglyceride levels >=200...

Read the full 203 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >